Jiangsu Gdk Biological Technology Co., Ltd (SHA:688670)

Market Cap	2.33B +22.3%
Revenue (ttm)	110.27M +36.1%
Net Income	-189.88M
EPS	-1.54
Shares Out	123.20M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	528,437
Open	18.87
Previous Close	18.89
Day's Range	18.64 - 19.20
52-Week Range	12.50 - 31.20
Beta	0.28
Analysts	n/a
Price Target	n/a
Est. Earnings	Oct 23, 2026

About SHA:688670

Jiangsu Gdk Biological Technology Co., Ltd engages in the research, development, production, and sale of human vaccines. It offers quadrivalent influenza virus split vaccines. The company human vaccine products are used for the prevention of various infectious diseases, including influenza, rabies, chickenpox, shingles, and pneumonia. Jiangsu Gdk Biological Technology Co., Ltd was founded in 2008 and is based in Taizhou, China.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 357
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688670

Financial Performance

In 2025, SHA:688670's revenue was 112.88 million, an increase of 39.70% compared to the previous year's 80.80 million. Losses were -178.46 million, 90.7% more than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 24, 2026

Data Sources Report a data error